Retro Biosciences Aims to Extend Human Lifespan with $1 Billion Funding Initiative

Retro Biosciences, a biotech company dedicated to age-related diseases fighting, is launching its bold plan to raise $1 billion in funding. The company is expected to add ten years to the healthy human lifespan through innovative therapies that target the root causes of aging. This substantial round of fundraising has been supported by prominent investors, including Sam Altman, who previously invested $180 million in the company as CEO of OpenAI.

About Retro Biosciences

Founded in 2021, Retro Biosciences is based in San Francisco and aims to develop therapies that prevent and reverse age-related diseases. The research focus of the company is divided into three primary areas:

• Cellular Reprogramming: It reprograms cells to become more youthful in state, possibly reversing aging at the cellular level.
• Autophagy Enhancement: It enhances the body’s natural cleaning process by clearing out damaged cells, improving cellular health.
• Plasma-Inspired Therapeutics: Creating therapies to build products found in blood plasma that restore tissues and organs to their youthful state.

All of these have been designed to target the root causes of aging, with the objectives of not only extending one’s lifespan but also health span—the time spent in good health.

Read also: Lindus Health raises $55M to expedite the clinical trial process

Funding Details

Retro Biosciences is now raising $1 billion in a Series A funding round. Sam Altman, who had initially put in $180 million to set up the company, is investing again, which means he still has faith in Retro’s mission. The company is already talking to some investors and one U.S. data center that will provide it with the computing muscle it needs to conduct its research.

How The Money Will Be Spent

A lot of the raised capital will go toward a number of flagship projects.

• Advancing Drug Development: This year, Retro expects to begin the first clinical trials for three of its drug candidates, one being a potential therapy for Alzheimer’s disease in Australia.
• Improving Research Infrastructure: Artificial intelligence models to design proteins that can reverse cellular aging; collaborations with data centers to lease the computing needed for complex simulations and analyses.
• These efforts are aimed at accelerating the development of therapies that can significantly impact human health and longevity.

The Role of Artificial Intelligence in Longevity Research

Retro Biosciences uses AI to accelerate drug discovery and development. It designs proteins with the help of AI models, which may be able to reverse cellular aging. This accelerates the identification of potential therapeutic candidates. This approach would make research much more efficient and precise, potentially breaking through age-related diseases.

Read also: Tune Therapeutics Secures $175M to Advance Epigenetic Editing Therapies

Future Prospects

With the expected influx of $1 billion in funding, Retro Biosciences is all set to make rapid strides in longevity research. It aims at the following strategies:

• Develop Clinical Trials: Testing the human drug candidates for safety and effectiveness, such as those for age-related diseases, like Alzheimer’s.
• Expand Research Collaborations: Tie-up with academic institutions, healthcare providers, and technology companies to boost the research and development efforts.
• Scale Operations: Expanding the team of scientists, engineers, and support personnel to meet an expanded scope of research and development activities.

These strategies are aligned to the mission of Retro, the extension of human lifespan with a healthy state as well as relief from age-related diseases.